[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631969":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":25,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Sulaimani","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with BPH treated with Rezum",null,"Consecutive patients with benign prostatic hyperplasia who underwent Rezūm water vapor thermal therapy at a single center under local anesthesia with intravenous sedation.",[13],"Device: Rezum Water Vapor Thermal Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Rezum Water Vapor Thermal Therapy","Transurethral convective water vapor thermal therapy used for the treatment of benign prostatic hyperplasia.",[9],[21],{"name":22,"affiliation":23,"role":24},"Ali K M.Sami, M.B.Ch.B., F.I.B.M.S.( PhD)","College of Medicine, University of Sulaimani","PRINCIPAL_INVESTIGATOR",[26],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Royal Hospital","Sulaymaniyah","Kurdistan Region of Iraq (kri)","46001","Iraq","IQ",{"type":34,"coordinates":35},"Point",[36,37],45.4329,35.56496,{"lat":37,"lon":36},{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","ALI KAMAL M. SAMI","Doctor, Urologist,","100631969","safety-efficacy-and-short-term-outcomes-of-rezm-water-vapor-thermal-therapy-for-benign-prostatic-hyperplasia-under-local-anesthesia-with-intravenous-sedation-a-single-center-retrospective-study-of-129-patients-in-the-kurdistan-region-of-iraq-100631969",false,"NCT07507591","Safety, Efficacy, and Short-Term Outcomes of Rezūm Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia Under Local Anesthesia With Intravenous Sedation: A Single-Center Retrospective Study of 129 Patients in the Kurdistan Region of Iraq","Inclusion Criteria:\n\n1. Male patients aged 45 years or older.\n2. Moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPSS ≥8).\n3. Maximum urinary flow rate (Qmax) less than 15 mL\u002Fs on uroflowmetry.\n4. Prostate volume 30 to 120 g on transrectal or transabdominal ultrasonography.\n5. Failure of medical therapy or intolerance to medical therapy.\n6. Catheter-dependent urinary retention secondary to benign prostatic hyperplasia in patients who were not candidates for or declined conventional surgical intervention.\n7. Consecutive patients who underwent Rezūm water vapor thermal therapy during the study period.\n\nExclusion Criteria:\n\n1. Pre-existing erectile dysfunction not attributable to benign prostatic hyperplasia medication side effects.\n2. Retrograde ejaculation not caused by alpha-blocker therapy.\n3. Lower urinary tract symptoms attributable to causes other than benign prostatic hyperplasia, including neurogenic bladder or bladder overactivity unrelated to benign prostatic hyperplasia.\n4. History of previous bladder surgery, prostate surgery, or urethral stricture surgery.\n5. Presence of vesical calculi.\n6. Confirmed neurogenic bladder.\n7. Suspected or confirmed prostate malignancy.","MALE","45 Years","96 Years",{"count":53,"type":54},129,"ACTUAL","OBSERVATIONAL","This single-center retrospective study evaluates the safety, feasibility, and short-term clinical outcomes of Rezūm water vapor thermal therapy (WVTT) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in patients treated under local anesthesia with intravenous sedation. The study was conducted at Royal Hospital, Sulaymaniyah, Kurdistan Region of Iraq, and includes 129 consecutive patients aged 45 to 96 years with prostate volumes ranging from 30 to 120 grams. Outcomes assessed include symptom improvement, urinary flow, post-void residual volume, quality of life, erectile function, prostate volume reduction, catheter-related outcomes, perioperative complications, and retreatment rates. This study aims to provide real-world evidence regarding the use of Rezūm therapy in a high-comorbidity population and in a Middle Eastern clinical setting.",[58],"Benign Prostate Hyperplasia",[60,61,62,63,64,65,66,67,68,69,70],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms","Intravenous Sedation","Local Anesthesia","Prostate Enlargement","Urinary Retention","Minimally Invasive Therapy","Water Vapor Thermal Therapy","Rezum","LUTS","BPH","COMPLETED","2026-03-27",{"date":74,"type":54},"2026-04-02",{"date":76,"type":54},"2025-09-03",{"date":78,"type":54},"2026-03-12",{"name":41,"class":6},1]